|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0188 - 0.0220|
|52 Week Range||0.0112 - 0.0935|
|Beta (5Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO™ New Drug Submission (NDS). The last update was provided on November 18, 2022.
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclin
The Power Play by The Market Herald has announced the release of new interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold discussing their latest news.